-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 18, NMPA's official website showed that Tianjin Zhongxin Pharmaceutical's Gliclazide sustained-release tablets passed the consistency evaluation of generic drugs, making it the fifth company to pass the evaluation
.
Gliclazide sustained-release tablets are sulfonylurea hypoglycemic drugs, with terminal sales of more than 1.
3 billion yuan in Chinese public medical institutions in 2020
.
Gliclazide is a second-generation sulfonylurea oral hypoglycemic drug commonly used in clinical practice.
The original manufacturer is Servier
.
Gliclazide extended-release tablet is its extended-release dosage form with a relatively long duration of action and is used for adults with type 2 diabetes who are not adequately controlled by diet control, exercise therapy and weight loss alone
.
According to data from Minet.
com, in 2020, the sales of terminal Gliclazide sustained-release tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
3 billion yuan; With sales of more than 600 million yuan, Servier occupies more than 70% of the market
.
Sales of Gliclazide sustained-release tablets in Chinese public medical institutions (unit: ten thousand yuan) Source: Minet.
com Five companies have passed the consistency evaluation, including Beijing Fuyuan Pharmaceutical, Yichang Renfu Pharmaceutical, Tianjin Junan Bio, Jiangsu Yellow River Pharmaceutical, and Tianjin Zhongxin Pharmaceutical
.
Up to now, Tianjin Zhongxin Pharmaceutical has reviewed 3 varieties, including antipsychotic tiapride hydrochloride tablets, diabetes drug metformin hydrochloride tablets and gliclazide sustained-release tablets
.
.
Gliclazide sustained-release tablets are sulfonylurea hypoglycemic drugs, with terminal sales of more than 1.
3 billion yuan in Chinese public medical institutions in 2020
.
Gliclazide is a second-generation sulfonylurea oral hypoglycemic drug commonly used in clinical practice.
The original manufacturer is Servier
.
Gliclazide extended-release tablet is its extended-release dosage form with a relatively long duration of action and is used for adults with type 2 diabetes who are not adequately controlled by diet control, exercise therapy and weight loss alone
.
According to data from Minet.
com, in 2020, the sales of terminal Gliclazide sustained-release tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
3 billion yuan; With sales of more than 600 million yuan, Servier occupies more than 70% of the market
.
Sales of Gliclazide sustained-release tablets in Chinese public medical institutions (unit: ten thousand yuan) Source: Minet.
com Five companies have passed the consistency evaluation, including Beijing Fuyuan Pharmaceutical, Yichang Renfu Pharmaceutical, Tianjin Junan Bio, Jiangsu Yellow River Pharmaceutical, and Tianjin Zhongxin Pharmaceutical
.
Up to now, Tianjin Zhongxin Pharmaceutical has reviewed 3 varieties, including antipsychotic tiapride hydrochloride tablets, diabetes drug metformin hydrochloride tablets and gliclazide sustained-release tablets
.
